Imukin

Interferon gamma-1b, the active ingredient in Imukin, is a cytokine presented as a sterile solution for subcutaneous use. It modulates immune responses and is indicated for specific rare immunodeficiency and bone disorders in pediatric and adult patients.

GNH USA supplies Imukin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imukin is a recombinant cytokine used to treat disorders that involve defective immune activation or abnormal bone marrow function.

Chronic granulomatous disease (CGD): reduces the frequency and severity of bacterial and fungal infections in patients with defective NADPH‑oxidase activity. Severe malignant osteopetrosis (MOP): stimulates osteoclast development and improves hematopoiesis, helping to alleviate bone marrow failure in affected children. Autosomal recessive IFN‑γ receptor deficiency (investigational): aims to restore immune signaling pathways in patients with genetic receptor defects.

Common Side Effects: - Flu‑like symptoms such as fever, chills, and muscle aches. - Injection‑site reactions including redness, swelling, or pain. - Headache and fatigue. - Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema). - Autoimmune hepatitis or elevated liver enzymes. - Hematologic abnormalities such as neutropenia or anemia. - Pulmonary edema or respiratory distress. - Significant depression or mood changes.

Imukin requires careful monitoring due to its immunomodulatory activity. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown effects; consider discontinuation or monitor infant. - Renal impairment: adjust monitoring of renal function and drug levels. - Hepatic impairment: assess liver enzymes regularly. - Autoimmune disorders: evaluate risk of disease exacerbation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Interferon gamma‑1b may interact with several agents that affect immune function or blood parameters.

Major Interactions (Avoid): - Live vaccines: may reduce vaccine efficacy; avoid concurrent administration. - High‑dose corticosteroids or other potent immunosuppressants: can blunt therapeutic response. - Antiviral agents such as ribavirin: potential additive toxicity.

Moderate Interactions (Monitor Closely): - Cytotoxic chemotherapy: monitor complete blood counts for additive myelosuppression. - Anticoagulants (e.g., warfarin): observe INR for possible changes. - Other biologic immunomodulators: assess for overlapping immune effects.